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Abstract Migraine with aura affects *20–30 % of mi-
graineurs and it is much less common than migraine
without aura. The aim of this study was to compare the
efﬁcacy of frovatriptan 2.5 mg and zolmitriptan 2.5 mg in
the treatment of migraine with aura. Analysis was carried
out in a subset of 18 subjects with migraine with aura
(HIS criteria) out of the 107 enrolled in a multicenter,
randomized, double-blind, cross-over study. According to
the study design, each patient had to treat three episodes
of migraine in no more than 3 months with one drug,
before switching to the other treatment. The rate of pain-
free episodes at 2 h was signiﬁcantly (p\0.05) larger
under frovatriptan (45.8 %) than under zolmitriptan
(16.7 %). Pain free at 4 h, pain relief at 2 and 4 h and
recurrent episodes were similar between the two treat-
ments, while sustained pain-free episode was signiﬁcantly
(p\0.05) more frequent during frovatriptan treatment
(33.3 vs. 8.3 % zolmitriptan). Our study suggests that
frovatriptan is superior to zolmitriptan in the immediate
treatment of patients with migraine with aura, and it is
capable of maintaining its acute analgesic effect over
48 h.
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Introduction
Approximately 20–30 % of people suffering from migraine
headaches perceive an aura, namely a transient visual,
sensory, language, or motor disturbance signaling the
imminent occurrence of a migraine attack [1].
Though migraine with aura shares frequently the same
clinical features with respect to the headache of migraine
without aura, nevertheless the auras can cause anxiety
and distress in the patient, being particularly disabling
[2].
Triptans are generally considered the most effective
acute treatment for migraine [3, 4]. However, pharmaco-
logical trials usually include mixed population of patients
or predominantly migraineurs without aura, and do not
speciﬁcally address drug efﬁcacy in patients with aura [5].
To bring new evidence supporting the efﬁcacy of trip-
tans also in patients with migraine with aura, we analyzed a
subgroup of such patients, included in a large randomized,
double-blind, cross-over, comparative study of frovatriptan
versus zolmitriptan [7].
V. Tullo  M. Curone  G. Bussone
Departement of Neuroscience, National Neurological Institute
Carlo Besta, Milan, Italy
G. Allais (&)  C. Benedetto
Department of Gynecology and Obstetrics, Women’s Headache
Center, University of Turin, Via Ventimiglia 3,
10126 Turin, Italy
e-mail: gb.allais@tiscali.it
M. D. Ferrari
Leiden Centre for Translational Neuroscience,
Department of Neurology, Leiden University Medical Centre,
Leiden, The Netherlands
S. Omboni
Italian Institute of Telemedicine, Varese, Italy
B. Colombo
Departement of Neurology, San Raffaele Hospital, Milan, Italy
D. Zava
Istituto Lusofarmaco d’Italia, Milan, Italy
123
Neurol Sci (2012) 33 (Suppl 1):S61–S64
DOI 10.1007/s10072-012-1043-8Methods
Study population
Male or female subjects, aged 18–65 years, with a current
history of migraine with or without aura, according to IHS
criteria, and with at least one migraine attack per month for
6 months prior to entering the study, were eligible for
participation in the main study [6, 7].
Details on study design and inclusion and exclusion
criteria are available elsewhere [6]. In this analysis mi-
graineurs with aura were selected. This condition was
deﬁned according to IHS criteria as at least two migraine
attacks with aura symptoms, consisting of visual and/or
sensory and/or speech symptoms [7].
Study design
The study had a multicenter, randomized, double blind,
cross-over design and has been extensively described in a
previous publication [6]. Brieﬂy, each patient received
frovatriptan 2.5 mg or zolmitriptan 2.5 mg in a randomized
sequence. After treating a maximum of three episodes of
migraine in no more than 3 months with the ﬁrst treatment,
the patient had to switch to the other treatment and asked to
treat a maximum of three episodes of migraine in no more
than 3 months with the second treatment.
The study involved three visits and each patient’s par-
ticipation time in the study did not exceed 6 months from
randomization. Subjects having no migraine episodes
during one of the two observation periods were excluded
from the study.
Randomization was done by blocks of 4. Blindness was
ensured by the over-encapsulation technique, i.e., by
inserting study drug tablets in capsules.
Data analysis
The present analysis was carried out in the subgroup of
patients with migraine with aura, who actually treated at
least one attack in each treatment period. Study endpoints
were [7] (a) pain-free episode at 2 and 4 h (absence of
migraine 2 and 4 h after intake of one dose of study drug
and without any rescue medication); (b) pain relief at 2 and
4 h (deﬁned as a decrease in migraine intensity from severe
or moderate to mild or none at 2 and 4 h); (c) recurrence
(pain free at 2 h and headache of any severity returning
within 48 h); and (d) sustained pain-free episode within
48 h (migraine attack which is pain free at 2 h, does not
recur and does not require the use of rescue medication or a
second study drug dose within 48 h).
Continuous variables were summarized by the calcula-
tion of average values and standard deviation (SD), while
categorical variables by computing the absolute value and
the frequency (as percentage). Endpoints were compared
between groups by generalized estimating equation analy-
sis. The level of statistical signiﬁcance was set at 0.05.
Results
The whole intention-to-treat population consisted of 107
patients, of whom 18 (16.8 %) had migraine with aura and
89 (83.2 %) had migraine without aura. No statistically
signiﬁcant difference was observed between the two sub-
groups of patients for baseline characteristics Table 1.
In the 18 patients suffering from migraine with aura, a
total of 48 headache attacks were reported: 24 treated with
frovatriptan (7.9 % of overall 304 episodes treated with
this drug) and 24 treated with zolmitriptan (8.0 % of the
overall 299 episodes).
Table 1 Baseline demographic
and clinical data of the migraine
patients with and without aura
of the ITT population
Data are shown as mean (±SD),
or absolute (n) and relative
frequency (%). P refers to the
statistical signiﬁcance of the
between-group differences
Migraine with
aura (n = 18)
Migraine without
aura (n = 89)
p
Age (years, means ± SD) 38.3 ± 6.1 38.1 ± 10.5 NS
Females (n, %) 16 (88.9) 69 (77.5) NS
Height (cm, means ± SD) 164.2 ± 5.7 166.2 ± 8.3 NS
Weight (kg, means ± SD) 61.1 ± 6.7 63.7 ± 12.2 NS
Age at onset of migraine
(years, means ± SD)
16.5 ± 9.6 16.3 ± 5.7 NS
Migraine attack duration[2 days (n, %) 3 (16.7) 14 (15.7) NS
MIDAS score (means ± SD) 21.6 ± 14.3 22.8 ± 16.1 NS
No use of triptans in the previous
3 months (n,% )
8 (44.4) 22 (24.7) NS
Patients with moderate attacks (n, %) 11 (61.1) 49 (55.1) NS
Patients with severe attacks (n, %) 7 (38.9) 40 (44.9) NS
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signiﬁcantly (p\0.05) larger under frovatriptan (45.8 %)
than under zolmitriptan (16.7 %). Conversely, pain-free
patients at 4 h were equally distributed between the two
treatment groups (58.3 % for frovatriptan and zolmitriptan,
p = NS). Proportions of patients with pain relief at 2 and
4 h and with recurrences did not signiﬁcantly differ
between frovatriptan (68.2, 72.7 and 27.3 %) and zolmi-
triptan (50.0, 63.6 and 50.0 %). Sustained pain-free epi-
sode was reported signiﬁcantly (p\0.05) more frequently
during frovatriptan treatment (33.3 vs. 8.3 % zolmitriptan,
Fig. 1).
Discussion
In this study, we aimed at speciﬁcally comparing efﬁcacy
of two triptans in migraine patients with aura through a
subgroup analysis of an original randomized, double-blind,
cross-over study [6]. Treatment with frovatriptan 2.5 mg
resulted in almost half of the patients free from pain at 2 h
and more than one-third showing sustained pain-free epi-
sode at 48 h, with proportions larger than those observed
under zolmitriptan. These results may have interesting
clinical implications.
To our knowledge, this is the ﬁrst direct head-to-head
comparative study of two triptans in patients experiencing
migraine with aura and strictly applying IHS criteria for
deﬁnition of study endpoints. Although there are no pre-
vious studies speciﬁcally comparing the efﬁcacy of frova-
triptan and zolmitriptan in migraine with aura, our results
are in line with those of previous randomized trials or
meta-analyses which also included a small sample of mi-
graineurs with aura and are also in line with the results
obtained in migraineurs without aura [8–11].
In conclusion, results of our multicenter, randomized,
double-blind trial support the indication of frovatriptan also
for the management of the acute attack of migraine with
aura. In this regard, frovatriptan seems to be superior to
zolmitriptan, though future well-designed large-scale
studies are needed to reinforce our observation, derived
from a limited sample of subjects retrospectively analyzed.
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